Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(50.0%)
Phase 2
4(50.0%)
8Total
Phase 1(4)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT02357966Phase 1Completed

Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.

Role: lead

NCT06526377Phase 2Not Yet Recruiting

Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis

Role: lead

NCT06590090Phase 2Not Yet Recruiting

Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment

Role: lead

NCT04825288Phase 1Active Not Recruiting

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Role: lead

NCT05363891Phase 2Completed

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

Role: lead

NCT05098080Phase 1Completed

Hutrukin to Analyze Safety and PK in Healthy Volunteers

Role: lead

NCT05363917Phase 2Unknown

Natrunix Versus Methotrexate in Rheumatoid Arthritis

Role: lead

NCT05099510Phase 1Unknown

Natrunix Safety PK Study in Healthy Volunteers

Role: lead

All 8 trials loaded